<DOC>
	<DOCNO>NCT01096056</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity GlaxoSmithKline Biologicals ' influenza vaccine GSK2186877A healthy child 6 35 month age . This Protocol Posting update follow Amendment 1 Protocol , Jun 2010 . The impacted section study design , outcome measure , intervention section number subject .</brief_summary>
	<brief_title>Trial Evaluate Safety Immunogenicity GSK Biologicals ' Influenza Vaccine GSK2186877A Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol . Children , male female , include , 6 35 month age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Age appropriate schedule childhood vaccination complete best parent ( ) /LAR ( ) knowledge . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Child care Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Prior receipt influenza vaccination ( seasonal pandemic ) plan administration study period . Planned administration vaccine 30 day prior 30 day study vaccine administration . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , mean prednisone &gt; 0.5 mg/kg body weight , equivalent . Inhaled topical steroid allow . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency . Any known suspected allergy constituent influenza routine paediatric vaccine , history severe adverse reaction previous vaccination ; history anaphylactictype reaction consumption egg protein . History neurological disorder seizure ( include febrile convulsion ) . Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Acute disease and/or fever time enrolment : Fever define temperature &gt; = 37.5°C oral , axillary tympanic setting , &gt; =38.0°C rectal setting . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever might enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Any condition , opinion investigator , render subject unfit participation study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Influenza</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccine</keyword>
</DOC>